[144] Surgery Partners, Inc. SEC Filing

Rhea-AI Filing Summary

Surgery Partners, Inc. (SGRY) Form 144 notice records a proposed sale of 100,000 shares of common stock through UBS Financial Services, scheduled approximately for 09/11/2025. The shares were acquired on 09/11/2025 via equity compensation (equity option exercise) from Surgery Partners, Inc. The filing reports the aggregate market value for the 100,000 shares as $2,201,000 and shows 128,209,410 shares outstanding. The filer also disclosed multiple recent sales by Wayne DeVeydt between 08/21/2025 and 09/08/2025, listing transaction sizes and gross proceeds for each sale. The notice includes the standard representations that the seller is not aware of any undisclosed material adverse information and that intentional misstatements are unlawful.

Positive

• Full compliance with Rule 144 disclosure by listing broker, planned sale date, and acquisition details
• Transparent reporting of recent insider sales with dates, amounts, and gross proceeds
• Clear statement that the seller does not possess undisclosed material adverse information

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine Rule 144 filing disclosing planned sale and recent insider transactions; appears procedural and disclosure-driven.

The filing documents a proposed sale of 100,000 common shares via UBS on 09/11/2025 and provides a full list of recent open-market sales by Wayne DeVeydt from 08/21/2025 through 09/08/2025 with amounts and gross proceeds. It also records the acquisition method for the 100,000 shares as an equity option exercise on 09/11/2025. For investors and compliance teams, this provides transparent, transaction-level detail required under Rule 144 but contains no operational or financial performance data about the issuer.

Corporate Governance Expert

TL;DR: Disclosure meets Rule 144 reporting standards; no additional governance issues are documented in this notice.

The notice includes the seller's certification regarding lack of undisclosed material adverse information and lists broker details and aggregate market value for the proposed sale. The filing serves to document insider liquidity and compliance with securities-sale disclosure obligations. The form contains no statements about changes in management, control transactions, or other governance actions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	100000	2201000	128209410	09/11/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
common	09/11/2025	equity compensation	Surgery Partners, Inc.			100000	09/11/2025	equity option exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/21/2025	100000	2299011
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/26/2025	25000	572717
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	08/27/2025	11865	271756
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/02/2025	25000	271756
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/03/2025	25000	560251
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/04/2025	25000	562756
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/05/2025	25000	563682
Wayne DeVeydt 9910 Cumberland Drive Fishers IN 46037	common	09/08/2025	2014	45207

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Surgery Partners (SGRY) report?

The Form 144 reports a proposed sale of 100,000 common shares via UBS on 09/11/2025, acquired on 09/11/2025 by equity option exercise.

Who conducted recent sales disclosed in the filing?

The filing lists Wayne DeVeydt as the seller for multiple transactions between 08/21/2025 and 09/08/2025, with individual amounts and gross proceeds provided.

What is the aggregate market value and shares outstanding shown?

The aggregate market value for the proposed 100,000-share sale is reported as $2,201,000, and the number of shares outstanding is 128,209,410.

How were the 100,000 shares acquired according to the filing?

The filing states the shares were acquired on 09/11/2025 through equity compensation via an equity option exercise.

Does the filing state any undisclosed adverse information about the issuer?

The signer represents that they do not know any material adverse information regarding the issuer that has not been publicly disclosed.